Trial Profile
Safety of SCH 527123 in Subjects With Neutrophilic Asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Navarixin (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 01 Jul 2012 Results published in Clinical and Experimental Allergy.
- 28 Apr 2012 Additional trial location added as reported by European Clinical Trials Database.
- 19 May 2010 Results will be presented at the 106th International Conference of the American Thoracic Society.